ClinicalTrials.gg
Not yet recruitingNCT07345117TREAT-EDUpdated Mar 18, 2026

Cost-effectiveness and Implementation of a Transdiagnostic Internet-based Intervention for Emotional Disorders in Community Care.

An interventional study of Internet-based psychological intervention and Treatment as usual (TAU) in Emotional Disorders, Depression Anxiety Disorder and Depression Disorders, sponsored by Universitat Jaume I. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Universitat Jaume I · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Anxiety Disorders by Universitat Jaume I — 5 open to participants now, 5 under way, none of them phase 3. Anxiety Disorders · Universitat Jaume I.

Planned enrollment
3rd of 11
200 · median 158
Started
2026
the only one that year
No phase
11 of 11
5 open now
Registered
11th of 11
by date

Among the 11 studies in Anxiety Disorders by Universitat Jaume I, this one is the 3rd largest by planned enrollment, is the only one that started in 2026, is one of 11 with no phase, and was the 11th registered.

Anxiety Disorders

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

Browse Anxiety Disorders studies →

Open to participants now

5 of the 11 studies in Anxiety Disorders by Universitat Jaume I are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 947 Anxiety Disorders studies recruiting now, 423 (45%) set no upper age limit and 455 (48%) stop at 75 or younger; 233 take children under 18; 319 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Anxiety Disorders by Universitat Jaume I, or all of them as a file.
02

Study summary

Emotional disorders (ED) are one of the leading causes of disability. They are highly prevalent and have an impact on quality of life. Addressing them places an overload on the National Health System (NHS), generating waiting lists and limiting appropriate care. The need for cost-effective solutions has led to the consideration of the transdiagnostic approach and the use of digital solutions. Both perspectives have demonstrated efficacy in a large number of randomized clinical trials. As a result, investment in digital health interventions is on the rise to improve access to care in overburdened healthcare systems. However, their integration and implementation in health systems remains limited. Implementation Science emerges to facilitate the integration of interventions into clinical practice through specific strategies that overcome barriers and optimize their sustainability. The objective of this project is to examine the effectiveness, economic costs and feasibility of implementing an online psychological treatment program for emotional disorders in mental health services. The Mutua and UJI teams have already carried out the transfer of the online program. In order to facilitate the adoption and sustainability of this program and that it can be used by mental health professionals in daily practice, a hybrid design 1 study will be carried out in which not only the efficacy but also the possibility of adoption and the analysis of economic costs in comparison with the usual treatment will be evaluated.

Read the detailed description

The World Health Organization (WHO) defines mental health as "a state of well-being in which every individual realizes his or her potential, can cope with the stresses of life, can work productively and fruitfully, and is able to make a contribution to his or her community." Many people do not achieve this state of well-being, or even if they do, they lose it at some point in their lives. When this happens, it can take the form of a mental disorder, the most prevalent being depressive and anxiety disorders, which affect around 6% of the population in Spain, causing a major impact on their social, work, and personal lives. In the wake of the COVID pandemic, there has been greater awareness in society of the importance of mental health.

However, despite this and despite the availability of effective pharmacological and psychological treatments that can significantly alleviate the symptoms of many mental disorders, health systems are not responding adequately to people with mental disorders. A study exploring mental health care in 84 countries, including Spain (Moitra et al., 2022), found that only 23% of people with depression in high-income countries and 3% in middle-income countries received minimally adequate treatment for their problem. This indicates that the problem goes beyond a health issue; it is a social and ethical problem, since without adequate treatment, many mental disorders have very negative consequences that significantly reduce well-being, satisfaction, and quality of life and cause social inequalities.

Possible solutions include increasing the number of professionals and organizing the provision of services more efficiently, from prevention to specialized care, including primary care. In this regard, there is a very solid line of research that has shown that online psychological treatments are as effective as face-to-face treatments for people with moderate depression and anxiety disorders. This project is part of the objective of optimizing mental health services by incorporating an online treatment program in order to increase citizens' access to effective psychological treatments.

The researchers involved in this application form a team that combines healthcare work with scientific work in order to implement an online transdiagnostic treatment program, going beyond individual face-to-face therapy, increasing diversity in the ways psychotherapy is administered, being flexible, and expanding the range of services offered. The team at the Universitat Jaume I (UJI) has developed and validated the "UJI online transdiagnostic protocol" in rigorous clinical trials and with the collaboration of affected individuals (user-centered design), which is effective in the short and long term for depression and anxiety. Over the past year, the UJI team and the Mutua Terrassa team, through a transfer agreement, have integrated the program into Mutua's technology platform. This application aims to promote the adoption and sustainability of this program as an additional alternative available to mental health professionals at the two mental health centers run by Mutua Terrassa, which serve a population of more than 200,000 inhabitants.

The idea is to offer this program to people with moderate depression and/or anxiety so that professionals can intensify face-to-face care for other patients with more serious conditions. A clinical trial will be conducted to compare the effectiveness and costs of the online program with the usual treatment received by patients. In addition, the opinions of professionals and patients about the program will be evaluated, and the barriers and facilitators of incorporating the online program into services will be analyzed. The results will indicate the usefulness of this alternative. If the results are positive, an affordable, evidence-based alternative will be available that will increase the scope and scalability of treatments, which will be more integrated into people's daily lives, expanding the settings in which interventions are provided, with the acceptance of those involved. The project's actions include a plan to disseminate the results to society through social media networks belonging to both the UJI and Mutua; the organization of a specific conference on the project's results for primary care and specialist professionals at Mutua and another conference for patient and user associations; and holding meetings with managers who can make decisions about the sustainability of the program and its adoption in other services (General Directorate of Mental Health of the Valencian Community, management, health, and executive boards of Catsalut).

03

Conditions studied

  • Emotional Disorders
  • Depression Anxiety Disorder
  • Depression Disorders
  • Anxiety Disorders

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patient Inclusion Criteria:

  • Over 18 years of age.
  • Meet the diagnostic criteria for an anxiety or depressive disorder according to the (DSM-5).
  • Understand and read Spanish or Catalan.
  • Have access to the Internet and an email address
  • Give .

Patient Exclusion Criteria:

  • Diagnosis of schizophrenia, bipolar disorder, or alcohol or substance dependence.
  • High risk of suicide.
  • Presence of a medical condition that prevents psychological treatment.
  • Receiving other psychological treatment (other than TAU or the online program) during the study.
  • For participants in the online treatment condition with pharmacological treatment, this must be stabilized (doses cannot be changed or increased during the study, only reduced).

Inclusion Criteria for mental health Professionals:

  • They work at centers participating in the study.
  • They agree to participate in the study.
  • They sign an informed consent form.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Transdiagnostic intervention protocol

    Internet-based psychological intervention (UJI online transdiagnostic protocol). This protocol, based on the transdiagnostic perspective, offers the possibility of applying a single psychological treatment for different emotional disorders by proposing that these disorders share a common vulnerability which, associated with certain stress factors, gives rise to different manifestations of this vulnerability (depression and various anxiety disorders).

    Behavioral: Internet-based psychological intervention

  • Active comparator
    Treatment as usual (TAU)

    Standard treatment administered at participating health centers.

    Behavioral: Treatment as usual (TAU)

Interventions

  • BehavioralInternet-based psychological intervention

    This protocol consists of a set of techniques that have proven effective in improving the lives of people with emotional disorders and is designed to be applied via the Internet. Its objective is to teach strategies that improve the ability to regulate emotions in a more adaptive way. It includes the following core therapeutic components, aimed primarily at regulating negative affect: a) emotional awareness focused on the present moment and acceptance, b) cognitive flexibility, c) emotional and behavioral avoidance, and d) exposure to emotional experiences (interoceptive and situational). In addition, the protocol also includes traditional evidence-based components for the treatment of emotional disorders, such as psychoeducation, motivation for change, and relapse prevention. Finally, it also includes a specific component for regulating positive affect, with the aim of promoting psychological strengths and improving well-being.

    Also known as: UJI online transdiagnostic protocol

  • BehavioralTreatment as usual (TAU)

    TAU may include pharmacological treatment (antidepressants and/or anxiolytics), psychological treatments (case management, group therapy, empathic listening, and counseling and advice), mental health nursing follow-up with psychosocial interventions, or a combination thereof. Participants in TAU and receiving treatment outside the center will be excluded from the study. The specific treatment received by each patient will be recorded. After the study, TAU participants will be given access to online treatment.

06

What researchers measure

Primary outcomes

  1. Level of effectiveness of the intervention in reducing depressive symptoms using the Overall Depression Severity and Impairment Scale (ODSIS)

    Scores equal to or greater than 5 discriminate patients with clinical depressive symptoms.

    Time frame: Baseline, at the end of the intervention and follow-up at 3, 6, 9 and 12 months.

  2. Level of effectiveness of the intervention in reducing anxiety symptoms using the Overall Anxiety Severity and Impairment Scale (OASIS)

    Scores equal to or greater than 7 discriminate patients with symptoms of clinical anxiety.

    Time frame: Baseline, at the end of the intervention and follow-up at 3, 6, 9 and 12 months.

  3. Level of effectiveness of the intervention in improving positive and negative affect using the Positive and Negative Affect Scale (PANAS)

    2 subscales: Negative and Positive Affect. Higher scores in each subscale indicates more neuroticism and positive affect, respectively.

    Time frame: Baseline, at the end of the intervention and follow-up at 3, 6, 9 and 12 months.

  4. Level of effectiveness of the intervention in improving quality of life using the EuroQoL-5D-3L

    This questionnaire describes health status in terms of five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) according to five levels of severity. The experimental group will experience a more substantial improvement in quality of life compared to the TAU group, as evidenced by superior outcomes on the European Quality of Life 5D (EUROQOL).

    Time frame: Baseline, at the end of the intervention and follow-up at 3, 6, 9 and 12 months.

Secondary outcomes

  1. Level of acceptability of the intervention using the System Usability Scale (SUS)

    Cut-off: a score of 68 and higher is considered acceptable usability.

    Time frame: At the end of the intervention and follow-up at 3, 6, 9 and 12 months.

  2. Level of acceptability of the intervention using the Acceptability of Intervention Measure (AIM)

    Cut-off scores for interpretation are not yet available; however, higher scores indicate greater acceptability.

    Time frame: At the end of the intervention and follow-up at 3, 6, 9 and 12 months.

  3. Level of acceptability of the intervention using the Client Satisfaction Questionnaire adapted to Internet-based interventions (CSQ-I).

    Cut-off scores for interpretation are not yet available; however, higher scores indicate greater client satisfaction and acceptability.

    Time frame: At the end of the intervention and follow-up at 3, 6, 9 and 12 months.

  4. Level of feasibility of the intervention using the Feasibility of Intervention Measure (FIM)

    Cut-off scores for interpretation are not yet available; however, higher scores indicate greater feasibility.

    Time frame: At the end of the intervention and follow-up at 3, 6, 9 and 12 months.

  5. Level of feasibility of the intervention using passive data collected by the platform.

    Program usage metrics (module completion, dropout, and frequency of use).

    Time frame: At the end of the intervention and follow-up at 3, 6, 9 and 12 months.

  6. Level of appropriateness of the intervention using the Intervention Appropriateness Measure (IAM)

    Cut-off scores for interpretation are not yet available; however, higher scores indicate greater appropriateness.

    Time frame: At the end of the intervention and follow-up at 3, 6, 9 and 12 months.

  7. Barriers and facilitators to intervention implementation measured quantitatively with the Pragmatic Context Assessment Tool (pCAT)

    Time frame: At the end of the intervention and follow-up at 3, 6, 9 and 12 months.

  8. Barriers and facilitators to intervention implementation measured qualitatively with semi-structured interviews and focus groups

    Following the Consensual Qualitative Research (CQR) guidelines

    Time frame: At the end of the intervention and follow-up at 3, 6, 9 and 12 months.

  9. Cost analysis - Initial technology investment costs

    Time frame: At the end of the intervention and follow-up at 3, 6, 9 and 12 months.

  10. Cost analysis - Direct costs using the ICT-P adult questionnaire

    Time frame: At the end of the intervention and follow-up at 3, 6, 9 and 12 months.

  11. Cost analysis - Indirect costs using the Productivity Costs Questionnaire (iPCQ)

    Time frame: At the end of the intervention and follow-up at 3, 6, 9 and 12 months.

07

Study locations

1 site
  • Laboratorio de Psicología y Tecnología (LabPsiTec)
    Castellon, Castellon 12071, Spain
    • Monica Conesa Gimenez, Psychology · Contactconem@uji.es · +34 646873875
    • Azucena Garcia Palacios, Psychology · Principal investigator
    • Rosa Lorente Catala, Psychology · Sub investigator
08

References and documents

Publications

  • Gonzalez-Robles A, Suso-Ribera C, Diaz-Garcia A, Garcia-Palacios A, Castilla D, Botella C. Predicting response to transdiagnostic iCBT for emotional disorders from patient and therapist involvement. Internet Interv. 2021 Jun 20;25:100420. doi: 10.1016/j.invent.2021.100420. eCollection 2021 Sep. PubMed 34401379 ↗
  • Gonzalez-Robles A, Roca P, Diaz-Garcia A, Garcia-Palacios A, Botella C. Long-term Effectiveness and Predictors of Transdiagnostic Internet-Delivered Cognitive Behavioral Therapy for Emotional Disorders in Specialized Care: Secondary Analysis of a Randomized Controlled Trial. JMIR Ment Health. 2022 Oct 31;9(10):e40268. doi: 10.2196/40268. PubMed 36315227 ↗
  • Diaz-Garcia A, Gonzalez-Robles A, Garcia-Palacios A, Fernandez-Alvarez J, Castilla D, Breton JM, Banos RM, Quero S, Botella C. Negative and Positive Affect Regulation in a Transdiagnostic Internet-Based Protocol for Emotional Disorders: Randomized Controlled Trial. J Med Internet Res. 2021 Feb 1;23(2):e21335. doi: 10.2196/21335. PubMed 33522977 ↗
  • Gonzalez-Robles A, Diaz-Garcia A, Garcia-Palacios A, Roca P, Ramos-Quiroga JA, Botella C. Effectiveness of a Transdiagnostic Guided Internet-Delivered Protocol for Emotional Disorders Versus Treatment as Usual in Specialized Care: Randomized Controlled Trial. J Med Internet Res. 2020 Jul 7;22(7):e18220. doi: 10.2196/18220. PubMed 32673226 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Jan 2027, 9 months later.

Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 9 months is below that.

Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Jan 15, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Jan 15, 2027
CompletionEst.
Jan 1, 2029
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07345117
Lead sponsor
Universitat Jaume I
Collaborators
Hospital Mutua de Terrassa
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Jan 15, 2027 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Mar 18, 2026

Study contacts

Monica Conesa-Gimenez, Psychology
Contact
conem@uji.es
+34 646-873-875
Azucena Garcia-Palacios, Psychology
study director · Universitat Jaume I

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion